Ney Carter Borges։ Clinical Importance of Coronary Microcirculation in MINOCA and INOCA
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Clinical Importance of Coronary Microcirculation in MINOCA and INOCA
Coronary microvascular dysfunction (CMD) plays a central and increasingly recognized role in the pathophysiology of angina with non-obstructive coronary arteries, including both myocardial infarction with non-obstructive coronary arteries (MINOCA) and ischemia with non-obstructive coronary arteries (INOCA). Although epicardial coronary arteries may appear angiographically normal or minimally diseased, impairment of the coronary microcirculation leads to inadequate myocardial perfusion, ischemia, and adverse clinical outcomes.
Epidemiological data indicate that INOCA affects up to 40–50% of patients undergoing coronary angiography for angina, with a higher prevalence in women, particularly post-menopausal. In MINOCA, which accounts for approximately 5–10% of all myocardial infarctions, coronary microvascular dysfunction, microvascular spasm, and microembolization are implicated in up to 50–60% of cases when systematically investigated with invasive or advanced imaging techniques.
From a prognostic perspective, CMD is far from benign. Patients with INOCA and documented microvascular dysfunction have a 2–4-fold increased risk of major adverse cardiovascular events (MACE), including cardiovascular death, heart failure hospitalization, and recurrent angina. Reduced coronary flow reserve (CFR <2.0) has been independently associated with a 3-fold increase in cardiovascular mortality over long-term follow-up. Similarly, MINOCA patients demonstrate annual MACE rates of 3–5%, comparable to those observed in patients with obstructive coronary artery disease.
Recognition of coronary microcirculatory pathology in MINOCA and INOCA is therefore critical, not only for accurate diagnosis but also for risk stratification and targeted therapy, shifting clinical focus beyond the epicardial arteries toward the microvascular substrate of ischemic heart disease.
1. Taqueti VR, Di Carli MF.
Coronary microvascular disease: mechanisms and clinical implications.
J Am Coll Cardiol. 2018.
2. Ong P, Camici PG, et al.
Coronary microvascular dysfunction and microvascular angina.
Eur Heart J. 2018.
3. Tamis-Holland JE, et al.
MINOCA: contemporary diagnosis and management.
Circulation. 2019.
4. Pasupathy S, et al.
Myocardial infarction with nonobstructive coronary arteries.
Circulation. 2015.
5. Knuuti J, et al.
ESC Guidelines on chronic coronary syndromes.
Eur Heart J. 2020.”

Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery
-
Aug 31, 2026, 14:06Khalid Alfawaz: Signed Consent Doesn’t Always Mean Informed
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?